TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9721060

Group type: EXPERIMENTAL
Intervention: Cycling training program (Group I)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cycling and jogging training program (Group II)
Number of subjects: 38
Study: 7867237

Group type: EXPERIMENTAL
Intervention: Rowing Ergometry (RE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cycle Ergometry (CE)
Number of subjects: 10
Study: 2910656

Group type: EXPERIMENTAL
Intervention: Erythromycin, neomycin, and cefazolin
Number of subjects: 155

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 155
Study: 4928171

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Phenazocine
Number of subjects: 2
Study: 31266155

Group type: EXPERIMENTAL
Intervention: OLE (50 mg oleuropein) consumed in capsule form 3 times a day for 1 week
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 28501418

Group type: EXPERIMENTAL
Intervention: Wrist-worn GENEActiv accelerometer
Number of subjects: 89

Group type: COMPARATOR
Intervention: Hip-worn ActiGraph (GT3X+) accelerometer
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Wrist-worn accelerometer
Number of subjects: 89
Study: 25959529

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 24246433

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Experimental arm (social network intervention)
Number of subjects: 357
Study: 21736770

Group type: EXPERIMENTAL
Intervention: Whey protein (Wh, low-viscous liquid)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Casein (Cas, high-viscous liquid)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Casein cross-linked with transglutaminase (Cas-TG, rigid gel)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Whey protein (Wh)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Casein (Cas)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Casein cross-linked with transglutaminase (Cas-TG)
Number of subjects: 8
Study: 19747429

Group type: EXPERIMENTAL
Intervention: Azelastine 0.15% nasal spray (2 sprays/nostril once daily)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study: 16534456

Group type: EXPERIMENTAL
Intervention: Multidose OPTI‐FREE RepleniSH (test RWD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% unpreserved unit-dose saline (control)
Number of subjects: 0
Study: 12723527

Group type: EXPERIMENTAL
Intervention: Oxandrolone and estrogen (n = 18)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Growth hormone (n = 17)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Untreated patients with spontaneous puberty (n = 10)
Number of subjects: 45
Study: 10840288

Group type: EXPERIMENTAL
Intervention: Increased anger, decreased vigor, increased confusion, negative attitude toward herpes, self-concealment, stress symptoms from genital herpes
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Increased anger, negative attitude toward herpes, decreased willingness to share personal information with a stranger
Number of subjects: 252
Study: 9044233

Group type: EXPERIMENTAL
Intervention: 50 rpm
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 80 rpm
Number of subjects: 58
Study: 8403798

Group type: EXPERIMENTAL
Intervention: Bombesin infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bombesin combined with loxiglumide
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 9
Study: 30219435

Group type: EXPERIMENTAL
Intervention: SE + HIIE
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HIIE + SE
Number of subjects: 9

Group type: COMPARATOR
Intervention: REST
Number of subjects: 9
Study: 27418381

Group type: EXPERIMENTAL
Intervention: ECT plus medication (venlafaxine plus lithium, four continuation ECT treatments over 1 month)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Medication only (venlafaxine plus lithium over 24 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ECT plus medication
Number of subjects: 120
Study: 24871703

Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT) administration
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 22310055

Group type: EXPERIMENTAL
Intervention: 3 or 6 months of neo‐adjuvant androgen deprivation therapy (NADT)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 802
Study: 20040034

Group type: EXPERIMENTAL
Intervention: Silica coating and silanization (n = 8 for each taper angle)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HF acid etching and silanization (n = 8 for each taper angle)
Number of subjects: 32
Study: 18817989

Group type: EXPERIMENTAL
Intervention: Re-expansive respiratory patterns associated to respiratory biofeedback (RBF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Biofeedback alone
Number of subjects: 60
Study: 15801991

Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.2 mg-0.8 mg) at 6 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.2 mg-0.8 mg) at 12 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.2 mg-0.8 mg) over three time points
Number of subjects: 37
Study: 12464951

Group type: EXPERIMENTAL
Intervention: Intranasal amphotericin B (20 mL of a 100 microg/mL solution twice daily)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intranasal amphotericin B
Number of subjects: 51
Study: 10451400

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Non-supplemented infants
Number of subjects: 88
Study: 8540704

Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus rifampin (n = 10)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus vancomycin (n = 10)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ceftriaxone alone (n = 11)
Number of subjects: 31
Study: 1721386

Group type: EXPERIMENTAL
Intervention: FK 506 + OLT
Number of subjects: 0

Group type: COMPARATOR
Intervention: CyA + OLT
Number of subjects: 0
Study: 6285939

Group type: COMPARATOR
Intervention: pivmecillinam
Number of subjects: 30

Group type: COMPARATOR
Intervention: mecillinam
Number of subjects: 30
Study: 31140443

Group type: EXPERIMENTAL
Intervention: CBT-based internet intervention with peer support
Number of subjects: 25

Group type: COMPARATOR
Intervention: Individual internet intervention designed to prevent PPD
Number of subjects: 25
Study: 28350567

Group type: EXPERIMENTAL
Intervention: Elective repair
Number of subjects: 496

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 496
Study: 26842694

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored intervention (game about alcohol with tailored feedback)
Number of subjects: 2649

Group type: COMPARATOR
Intervention: Control (baseline questionnaire only)
Number of subjects: 2649
Study: 24706596

Group type: EXPERIMENTAL
Intervention: Real-time alerts sent to the rapid response team (RRT)
Number of subjects: 571
Study: 22671949

Group type: EXPERIMENTAL
Intervention: Experimental group (theory-based interventions, 10 sessions of 45 minutes)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Experimental group (theory-based interventions)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Conventional group (traditional didactic teaching and drug refusal skills)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 441
Study: 20642555

Group type: EXPERIMENTAL
Intervention: Woohwangcheongsimwon suspension
Number of subjects: 14
Study: 17980221

Group type: EXPERIMENTAL
Intervention: Implementation intentions training intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 15080766

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily for 4 days plus lumiracoxib 400 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide/magnesium hydroxide antacid plus lumiracoxib 400 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lumiracoxib 400 mg alone
Number of subjects: 14
Study: 12546269

Group type: EXPERIMENTAL
Intervention: Risedronate (Actonel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study: 9835826

Group type: EXPERIMENTAL
Intervention: 0.243% sodium fluoride/silica dentifrice
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0.4% stannous fluoride/calcium pyrophosphate (positive control) dentifrice
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non-fluoridated placebo/calcium pyrophosphate (negative control) dentifrice
Number of subjects: 3
Study: 8074020

Group type: EXPERIMENTAL
Intervention: Molsidomine infusion
Number of subjects: 23

Group type: COMPARATOR
Intervention: Isosorbide dinitrate infusion
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 23
Study: 2552552

Group type: EXPERIMENTAL
Intervention: Fragmin administered subcutaneously twice daily (initial dose 100 U anti‐Xa/kg/12 h, adjusted based on anti‐Xa activity)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard heparin administered by continuous infusion (initial dose 240 UI/kg/12 h, adjusted based on APTT)
Number of subjects: 66
Study: 1194519

Group type: EXPERIMENTAL
Intervention: Failure plus ego involving instructions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Failure group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Test retest control group
Number of subjects: 36
Study: 30910410

Group type: EXPERIMENTAL
Intervention: Leukocyte- and platelet-rich fibrin (L-PRF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (socket sutured primarily)
Number of subjects: 34
Study: 29149418

Group type: EXPERIMENTAL
Intervention: Lateral Trendelenburg position (LTP)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Semirecumbent position (SRP)
Number of subjects: 395
Study: 25719937

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant (FAI)
Number of subjects: 641

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 641
Study: 24356595

Group type: EXPERIMENTAL
Intervention: Intensive therapy during the DCCT
Number of subjects: 0
Study: 22844471

Group type: EXPERIMENTAL
Intervention: Monounsaturated fat (MUFA) challenge
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fat (PUFA) challenge
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saturated fat (SFA) challenge
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Obese and obese diabetic subjects
Number of subjects: 42
Study: 19678782

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 45
Study: 21352112

Group type: EXPERIMENTAL
Intervention: OPUS treatment (assertive community treatment with family involvement and social skills training)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Standard treatment (contact with a community mental health centre)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: OPUS treatment
Number of subjects: 547
Study: 15668841

Group type: EXPERIMENTAL
Intervention: 1 degrees C increase in incubator temperature (T + 1 degrees C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1 degrees C decrease in incubator temperature (T - 1 degrees C)
Number of subjects: 20
Study: 12375299

Group type: EXPERIMENTAL
Intervention: New antidepressant (dose escalation)
Number of subjects: 10
Study: 10447621

Group type: EXPERIMENTAL
Intervention: Patients with spontaneous subcapital femoral neck fractures (n=7)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control group (n=267)
Number of subjects: 274
Study: 8665883

Group type: COMPARATOR
Intervention: diclofenac 75 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ketorolac 30 mg
Number of subjects: 50
Study: 2351365

Group type: EXPERIMENTAL
Intervention: Diazepam pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 0
Study: 94225

Group type: EXPERIMENTAL
Intervention: Topical application of 5% lidocaine and 5% prilocaine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Topical application of 5% lidocaine and 5% prilocaine used daily for 3-4 weeks
Number of subjects: 17
Study: 30368558

Group type: EXPERIMENTAL
Intervention: Rule-based categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information-integration categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YES/NO learning paradigm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contiguous, semi-contiguous, non-contiguous categories
Number of subjects: 0
Study: 31172520

Group type: EXPERIMENTAL
Intervention: Community Deliberation (CD)
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Citizens' Panel (CP)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 707
Study: 27423432

Group type: EXPERIMENTAL
Intervention: Quercetin (162 mg/d)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 24734909

Group type: EXPERIMENTAL
Intervention: Autogenous bone graft
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fresh frozen bone allograft
Number of subjects: 15
Study: 22891625

Group type: EXPERIMENTAL
Intervention: Fuji IX
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Hi-Dense
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Maxxion R
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Tooth survival
Number of subjects: 262
Study: 21804338

Group type: EXPERIMENTAL
Intervention: Laughter therapy (60 min, twice a week for 2 weeks, total of 4 sessions)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no laughter therapy)
Number of subjects: 67
Study: 19782873

Group type: EXPERIMENTAL
Intervention: Carpal tunnel surgery
Number of subjects: 116

Group type: COMPARATOR
Intervention: Non-surgical treatment (including hand therapy and ultrasound)
Number of subjects: 116
Study: 16678357

Group type: EXPERIMENTAL
Intervention: Biopsy from the incisura angularis
Number of subjects: 328

Group type: COMPARATOR
Intervention: Biopsy from the gastric antrum and corpus
Number of subjects: 328
Study: 14964742

Group type: EXPERIMENTAL
Intervention: Targeted biologic therapies
Number of subjects: 0
Study: 10743698

Group type: EXPERIMENTAL
Intervention: L-arginine 3 x 500 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8751104

Group type: EXPERIMENTAL
Intervention: Nd:YAG-laser iridotomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Surgical iridectomy
Number of subjects: 30
Study: 2205997

Group type: EXPERIMENTAL
Intervention: Regional intravenous block
Number of subjects: 99
Study: 6272442

Group type: EXPERIMENTAL
Intervention: antivitamin K with suloctidil
Number of subjects: 23

Group type: COMPARATOR
Intervention: antivitamin K alone
Number of subjects: 23
Study: 30924165

Group type: EXPERIMENTAL
Intervention: Lenograstim at 10 μg/kg/day for at least 4 consecutive days (early collection group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lenograstim at 10 μg/kg/day for at least 4 consecutive days (late collection group)
Number of subjects: 24
Study: 28668524

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg/h)
Number of subjects: 40
Study: 25296654

Group type: EXPERIMENTAL
Intervention: DHEA capsule 75 mg/day for at least 12 weeks before egg collection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for at least 12 weeks before egg collection
Number of subjects: 60
Study: 22725663

Group type: EXPERIMENTAL
Intervention: Curcumin 1000 mg capsules once daily for 14 days
Number of subjects: 18
Study: 20102876

Group type: EXPERIMENTAL
Intervention: Early hospital discharge (48-72 hours) with outpatient follow-up by an advanced practice nurse (APN)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard discharge planning and follow-up by treating physician without added nursing intervention
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study: 17050564

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 16246997

Group type: EXPERIMENTAL
Intervention: Intensive 2-day safety training program for staff
Number of subjects: 10558

Group type: EXPERIMENTAL
Intervention: Intensive 2-day safety training program for staff (in facilities with best program compliance)
Number of subjects: 10558
Study: 11858336

Group type: EXPERIMENTAL
Intervention: Impulse calculation incorporating the position of the center of pressure
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional method of estimating the impulse distribution beneath the foot
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Subjects with plantar fasciitis
Number of subjects: 32
Study: 9952148

Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 99

Group type: COMPARATOR
Intervention: Mivacurium and Vecuronium
Number of subjects: 99

Group type: COMPARATOR
Intervention: Succinylcholine and Rocuronium
Number of subjects: 99
Study: 7594343

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Famotidine 20 mg b.i.d.
Number of subjects: 22
Study: 2210021

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion (2 U bolus injection; 111 mU/min for 2 hours)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 10
Study: 7471334

Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonsurgical management
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonsurgical management (elective nonsurgical group)
Number of subjects: 100
Study: 30631161

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 28740204

Group type: EXPERIMENTAL
Intervention: Topically administered autologous APOSEC (12.5 × 106 PBMCs)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topically administered autologous APOSEC (25 × 106 PBMCs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (irradiated medium)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topically administered APOSEC (both doses)
Number of subjects: 10
Study: 25670636

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg on admission, followed by 20 mg/day)
Number of subjects: 220

Group type: COMPARATOR
Intervention: No statin treatment (control group)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Rosuvastatin and No statin treatment (control group)
Number of subjects: 220
Study: 24402637

Group type: EXPERIMENTAL
Intervention: Nanosphere Verigene® System
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (reduced metabolisers)
Number of subjects: 82
Study: 21334753

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg/Simvastatin 20mg (E10/S20)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Simvastatin 80 mg (S80)
Number of subjects: 83
Study: 18775622

Group type: EXPERIMENTAL
Intervention: Decision aid 1 (randomized in 390 women)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Decision aid 2 (randomized in 91 mutation carriers)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Decision aid 1 and 2
Number of subjects: 481
Study: 17519660

Group type: EXPERIMENTAL
Intervention: Bitriangular fascia sling (modified Crawford method)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Monotriangular fascia sling (modified Fox method)
Number of subjects: 19
Study: 16749654

Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/20 mg
Number of subjects: 247

Group type: COMPARATOR
Intervention: SIMVA 20 mg
Number of subjects: 247
Study: 14996777

Group type: EXPERIMENTAL
Intervention: Treatment guidelines tailored for the elderly with care management
Number of subjects: 598

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 598
Study: 10790552

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (MINI)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Microlaparoscopic cholecystectomy (MICRO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (Laparoscopic)
Number of subjects: 50
Study: 8988065

Group type: EXPERIMENTAL
Intervention: 2 mg/kg tramadol in extensive metabolizers
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 2 mg/kg tramadol in poor metabolizers
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 1503482

Group type: EXPERIMENTAL
Intervention: DWA2114R regimen
Number of subjects: 61

Group type: COMPARATOR
Intervention: CDDP regimen
Number of subjects: 61
Study: 6652642

Group type: EXPERIMENTAL
Intervention: Oral propranolol 80 mg, twice daily for 5 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral metoprolol 100 mg, twice daily for 5 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo after initial treatment
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous propranolol 10 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol 20 mg
Number of subjects: 19
Study: 30902820

Group type: EXPERIMENTAL
Intervention: BI 655064 (120 mg weekly for 12 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: BI 655064
Number of subjects: 67
Study: 29236628

Group type: EXPERIMENTAL
Intervention: BetterBirth program (coaching-based implementation of the WHO Safe Childbirth Checklist)
Number of subjects: 157689

Group type: COMPARATOR
Intervention: Control group (no coaching-based implementation of the WHO Safe Childbirth Checklist)
Number of subjects: 157689
Study: 27636757

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy in addition to conventional treatment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Only photodynamic therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 54